KIR2DL3產(chǎn)品信息
英文名稱:Killer cell immunoglobulin-like receptor 2DL3
中文名稱:殺傷細胞免疫球蛋白樣受體2DL3
靶點別稱:KIR2DL3,CD158b2
物種:Human
標簽:Fc Tag
屬性:Protein
標記:Unconjugated
表達區(qū)間及表達系統(tǒng)(Source)
Human KIR2DL3, Fc Tag (KI3-H5258) is expressed from human 293 cells (HEK293). It contains AA His 22 - His 245 (Accession # P43628-1).
Predicted N-terminus: His 22
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.0 kDa. The protein migrates as 65-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
殺傷細胞免疫球蛋白樣受體2DL3(KIR2DL3)也被稱為CD158抗原樣家族成員B2、KIR-023GB、殺傷抑制性受體cl2-3、MHC I類NK細胞受體、NKAT2a、NKAT2b、自然殺傷相關(guān)轉(zhuǎn)錄物2、p58自然殺傷細胞受體克隆cl-6、p58.2 MHC I類特異性NK受體、CD158b2和KIR2DL三,它是一種單程I型膜蛋白,屬于免疫球蛋白超家族。KIR2DL3是自然殺傷(NK)細胞上HLA-C等位基因(HLA-Cw1、HLA-Cw3和HLA-Cw7)的受體。KIR2DL3可以抑制NK細胞的活性,從而防止細胞裂解。
關(guān)鍵字: KIR2DL3;KIR2DL3蛋白;KIR2DL3重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。